Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib in Metastatic Anaplastic and Refractory Differentiated Thyroid Cancer
NCT02244463Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2015
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
A Phase 2 trial of sapanisertib in anaplastic thyroid cancer (ATC), differentiated thyroid cancer (DTC), thyroid cancer, sponsored by Dana-Farber Cancer Institute. Started Jul 2015; status: completed.
02
Drugs
sapanisertib
03
Conditions
anaplastic thyroid cancer (ATC)differentiated thyroid cancer (DTC)thyroid cancer
Beyond the preview
Go deeper on NCT02244463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02244463.